Kezdőlap・Részvénylista・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Nyitva

SzektorEgészségügy

66.18 1.69

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

63.88

Maximum

66.3

Fő mutatók
By Trading Economics
Bevétel	1.6B 2.7B
Értékesítés	-1B 11B
P/E Szektor átlag	17.524 64.641
Egy részvényre jutó nyereség	1.58
Osztalékhozam	4.03
Profit margin	23.309
Munkavállalók	32,500
EBITDA	1.5B 3.7B

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+0.57% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	4.03% 2.31%
Következő eredményjelentés	2026. okt. 29.
Következő korábbi osztalék dátum	2026. okt. 2.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	9.8B 128B
Előző nyitás	64.49
Előző zárás	66.18

Hangulat hírek alapján

By Acuity

48%

52%

146 / 340 Rangsor szerint Healthcare

Bristol-Myers Squibb Co. Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 3. 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

2026. júl. 31. 19:16 UTC

News

Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

2026. júl. 30. 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

2026. júl. 29. 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

2026. júl. 28. 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

2026. júl. 27. 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

2026. júl. 24. 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

2026. júl. 23. 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

2026. júl. 22. 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

2026. júl. 21. 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

2026. júl. 20. 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Társak összehasonlítása

Árváltozás

Bristol-Myers Squibb Co. Előrejelzés

Célár

By TipRanks

0.57% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 65.84 USD 0.57%

Magas 80 USD

Alacsony 40 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)Bristol-Myers Squibb Co. termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

20 ratings

Vétel

Tartás

Eladás

20 Wall Street elemző célárain alapulva a(z)Bristol-Myers Squibb Co. termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

146 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.